A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer (HNC).
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer (HNC). J Clin Oncol. 2008 May 20; 26(15_suppl):6067.